Top of this page
Skip navigation, go straight to the content

Our Science Our clinical studies Study Results Lay Summaries

Study Results Lay Summaries

Included here are study results summaries in lay terms for the studies that were considered ‘pivotal’ for the purpose of regulatory submission associated with UCB’s currently approved products – Cimzia®, Keppra®, Neupro®, and Vimpat®.

Going forward, UCB is committed to providing additional study results lay summaries as new products receive regulatory approval.